ACCESS TO ADVANCED HEALTH INSTITUTE
Doing business as AAHI
- SEATTLE, WA 98109-5001
- aahi.org (company website, opens in a new tab)
- Corporate Entity (Tax Exempt)
- SAM active
- No verified credentials yet
- CMMCNot on file
- SPRSNone
- FCLVisible to paid members
- Small Business
Registration and small-business types: SAM.gov, synced Nov 9, 2026. Compliance: self-attested by the company unless marked verified. The SPRS chip shows a range, never the exact score. How verification works
- 36-mo obligations
- $29.6M
- Awards on record
- 3
- Contract vehicles
- 0
- Verified credentials
- 0
Compliance posture: unverified (SAM.gov baseline only)
ACCESS TO ADVANCED HEALTH INSTITUTE has not claimed this profile. What you see comes from public SAM.gov and USAspending records; no one from the company has confirmed CMMC, SPRS or clearance details yet. Learn more about CMMC 2.0
About ACCESS TO ADVANCED HEALTH INSTITUTE
- Headquarters
- SEATTLE, WA 98109-5001
Identifiers
UEI and CAGE come from SAM.gov. Other identifiers are listed by the company.
- UEIEMQ1ANLATYS6
- CAGE06UF1
Capabilities & differentiators
No capability narrative yet
Compliance posture
No compliance posture published yet
Facility clearance
Facility clearance: visible to paid members
Clearance levels are shown only to paying members; TeamingIndex does not advertise clearances (NISPOM 32 CFR 117.9). Learn more about facility clearances · Compare plans
Past performance
- 36-month obligations
- $29.6M
- Awards on record
- 3
- Top funding agencies
- National Institutes of Health
Awards
75N93018C00025
Completed: Period of performance ended Aug 31, 2026IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.
Department of Health and Human Services · National Institutes of Health
- Obligated
- $10.8M
- Period of performance
- Sep 21, 2018 – Aug 31, 2026
75N93023C00018
Completed: Period of performance ended Jun 26, 2025BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS…
Department of Health and Human Services · National Institutes of Health
- Obligated
- $5M
- Period of performance
- Jul 5, 2023 – Jun 26, 2025
75N93019C00059
Completed: Period of performance ended Apr 25, 2025TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018
Department of Health and Human Services · National Institutes of Health
- Obligated
- $13.8M
- Period of performance
- Sep 9, 2019 – Apr 25, 2025
| Award | Agency | NAICS · PSC | Obligated | Period of performance | Recompete |
|---|---|---|---|---|---|
75N93018C00025 IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. | Department of Health and Human Services · National Institutes of Health | 541714 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $10.8M | Sep 21, 2018 – Aug 31, 2026 | Completed: Period of performance ended Aug 31, 2026 |
75N93023C00018 BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS… | Department of Health and Human Services · National Institutes of Health | 541715 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $5M | Jul 5, 2023 – Jun 26, 2025 | Completed: Period of performance ended Jun 26, 2025 |
75N93019C00059 TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 | Department of Health and Human Services · National Institutes of Health | 541714 · AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH | $13.8M | Sep 9, 2019 – Apr 25, 2025 | Completed: Period of performance ended Apr 25, 2025 |
Contract vehicles
No contract vehicles on file
Proven teaming graph
Primes it has worked under
No reported sub-awards as a subcontractor.
Subcontractors it has used
- EMORY UNIVERSITY
UEI S352L5PJLMP8
$1.2M
Subcontracted by this company · 1 sub-award · latest May 7, 2024
- National Institutes of Health
- “THIS STUDY WILL UTILIZE SYSTEMS IMMUNOLOGY APPROACHES TO INVESTIGATE THE IMMUNE SIGNATURES GENERATED BY OUR SARNA YFV VACCINE AND COMPARE THESE TO THE GOLD STANDARD YFV-17D LIVE-ATTENUATED VACCINE (YF-VAX). IMMUNE SIGNATURES WILL BE OBTAINED BY TRANSCRIPTOMIC ANALYSIS FOLLOWING PRIME AND BOOST IMMUNIZATIONS AND WILL CAPTURE BOTH EARLY INNATE AND ADAPTIVE IMMUNE SIGNATURES. IN ADDITION, WE WILL INVESTIGATE THE ANTIBODY REPERTOIRE GENERATED BY OUR VACCINE PLATFORM. WE WILL CORRELATE THESE SIGNATURES TO RESPONSE MEASURES OF CELLULAR AND HUMORAL IMMUNITY. CELLULAR IMMUNITY WILL FOCUS ON MARKERS OF MEMORY DEPOSITION FOR B CELLS (E.G., CD27) AND T CELLS AS A PRELIMINARY INDICATOR OF RESPONSE DURABILITY AND LONGEVITY.”
Source: USAspending.gov sub-award reports (FSRS) (opens in a new tab) · as of Nov 9, 2026 · Prime contractors report first-tier subcontracts of $30,000 or more. Amounts are reported sub-award values.
SBIR/STTR portfolio
No SBIR/STTR awards on record
Source: SBIR.gov award records (opens in a new tab) · sync date not recorded
FedRAMP offerings
No FedRAMP Marketplace listing
Source: FedRAMP Marketplace (opens in a new tab) · sync date not recorded
Exclusions & screening
SAM.gov exclusions
Not yet checked against SAM.gov exclusions.
Agencies generally may not award to excluded parties, and primes may not subcontract with them above the threshold in FAR 52.209-6 (except COTS items) without a compelling reason reported to the contracting officer (FAR 9.405, 9.405-2). Some exclusion types apply only to specific programs: read the record on SAM.gov.
Source: SAM.gov Exclusions (opens in a new tab) · sync date not recorded
Consolidated Screening List
No confirmed match on the Consolidated Screening List (screened Nov 13, 2026).
The list combines Commerce, State and Treasury export-control and sanctions lists. A “no match” result is a name-and-address screen, not an export-compliance determination.
Source: ITA Consolidated Screening List (opens in a new tab) · as of Nov 13, 2026
GSA CALC+ rate benchmark
No GSA CALC+ rates on record
Source: GSA CALC+ awarded ceiling rates (opens in a new tab) · sync date not recorded
NAICS, PSC & socio-economic status
NAICS codes
- 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)Primary
- 541714Research and Development in Biotechnology (except Nanobiotechnology)Small business under this code’s size standard
SAM.gov reports this entity as small under 1 of 2 NAICS codes. Size is determined per code (SBA size standards).
Product & service codes (PSC)
No PSC codes reported.
Teaming preferences
This company has not published teaming preferences.
Business development contact
No BD contact published
Corporate hierarchy
No parent entity reported in SAM.gov.
SBA counts affiliates when it determines whether a business is small (13 CFR 121.103), so a parent’s size can matter for set-aside work.
Data sources & provenance
SAM.gov
Registration, CAGE, NAICS, socio-economic status, corporate hierarchy and exclusions. Last synced Nov 9, 2026.
USAspending.gov
Prime award history and obligations (FPDS), synced nightly.
The contractor
Nothing yet: this profile has not been claimed by the company.
TeamingIndex verification
Credentials marked Verified were checked by a TeamingIndex reviewer; everything else is self-attested.
Corrections
Corrections to SAM.gov data must be made in SAM.gov; TeamingIndex picks them up on the next nightly sync. Go to SAM.gov (opens in a new tab)
Machine-readable: capability.md schema.org JSON-LD embedded in this page.
Zero CUI: TeamingIndex stores verification metadata only, never System Security Plans, POA&Ms or DD Form 254s.
Teaming
Ready to team with ACCESS TO ADVANCED HEALTH INSTITUTE?
Send an introduction and propose a mutual NDA. Their team is notified right away, and you can share the capability statement with your capture team.
